This unique series of four live, one-day meetings will provide expert reviews of the most meaningful and practice-changing data in the field of hematologic malignancies presented at ASH and other major society meetings held throughout 2010. In addition to didactic lectures, the format of the meeting also includes interactive “The Smartest Oncologist/Hematologist Quizzes.”

Sponsorship
This activity is sponsored by prIME Oncology.




Continuing Medical Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. 

prIME Oncology designates this live educational activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. 

Series Chair - Hagop Kantarjian, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas Ranjana Advani, MD Stanford University School of Medicine Stanford, California Kenneth Anderson, MD Dana-Farber Cancer Institute Boston, Massachusetts Jorge Cortes, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas Guillermo Garcia-Manero, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas Michael Kroll, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas John P. Leonard, MD Weill Medical College of Cornell University New York, New York Alan List, MD H. Lee Moffitt Cancer Center Tampa, Florida Sagar Lonial, MD Emory University - Winship Cancer Institute Atlanta, Georgia Reshma Mahtani, MD University of Miami Sylvester Comprehensive Cancer Center Deerfield Beach, Florida Peter McLaughlin, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas Stephan Moll, MD University of North Carolina Chapel Hill, North Carolina Susan O'Brien, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas

Robert Z. Orlowski, MD, PhD University of Texas, M. D. Anderson Cancer Center Houston, Texas Animesh Pardanani, MBBS, PhD Mayo Clinic Rochester, Minnesota Mikkael Sekeres, MD, MS Cleveland Clinic Cleveland, Ohio Neil Shah, MD, PhD University of California, San Francisco San Francisco, California Jorge Spinolo, MD, FACP Georgia Cancer Specialists Atlanta, Georgia Wendy Stock, MD University of Chicago Medical Center Chicago, Illinois Ayalew Tefferi, MD Mayo Clinic Rochester, Minnesota Julie Vose, MD University of Nebraska Medical Center Omaha, Nebraska Meir Wetzler, MD, FACP Roswell Park Cancer Institute Buffalo, New York Anas Younes, MD University of Texas, M. D. Anderson Cancer Center Houston, Texas Andrew Zelenetz, MD Memorial Sloan-Kettering Cancer Center New York, New York

The registration fee includes all activity materials, continental breakfast, lunch, and refreshment breaks.

Physicians

• Preregistration: $75.00
• Onsite registration: $100.00

Nurses

• Preregistration: $35.00*
• Onsite registration: $50.00*

*Supporting documentation of eligibility may be required.

Residents/Fellows
Residents and fellows are eligible for complimentary registration. Please contact hemehighlights@prIMEoncology.org for more information.

ONS Members

ONS members are eligible for discounted registration rates.  Please email hemehighlights@prIMEoncology.org with the name of your ONS chapter for more information.  

Preregistration will close on the following days for each meeting. After preregistration closes, the price will increase to the onsite rate.

 

• New York, New York – January 19, 2011
• Hollywood, Florida – February 2, 2011
• Houston, Texas – February 9, 2011
• Atlanta, Georgia – February 19, 2011

*Attendees may still register onsite the morning of the meeting.

prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.

The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.

Who Should Attend

This educational activity is intended for hematologists, oncologists, oncology specialist nurses, and other allied healthcare professionals interested in the management of hematologic malignancies.

Statement of Need 

As the rate at which clinical data are released increases and the numbers of therapeutic options grow, it is important for practicing oncologists and hematologists to stay abreast of these advances. Many community oncologists, hematologists, and other physicians involved in the management of hematologic malignancies do not attend major society meetings. Likewise, those who do, find the size and scope to be so broad and intensive that they require summaries of important data for ease of application to their daily practices. In order for rapid clinical progress to have a direct and immediate impact on patients’ lives, the newest findings must be readily applied by the practices of community oncologists and hematologists. In addition, the data presented at large clinical conferences are typically not framed in the context of the clinical practice of community oncologists/hematologists. prIME Oncology presents “Hematologic Malignancies Demystified: The Series—A Critical Appraisal of Data from 2010 and ASH,” to review, summarize, and interpret the most clinically significant data released in 2010 in an effort to meet this need.

Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Describe the latest management approaches for hematologic malignancies including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative disorders
• Evaluate difficult or unusual problems encountered by the practicing hematologist/oncologist and identify appropriate management options based on emerging data 
• Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies
• Summarize emerging data in the management of multiple hematologic malignancies and integrate new findings into clinical practice 
• Describe the role of coagulation medicine in deep vein thrombosis (DVT), pulmonary embolism (PE), thrombophilia, anticoagulation, and thrombocytopenia

Disclosure of Conflicts of Interest

prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME Activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure of Unlabeled Use of Agents

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturers' product information, and comparison with recommendations of other authorities.